Thursday, November 12, 2026

central-banks

3 articles

Fed holds rates above 4% while ECB cuts toward 2%, widening transatlantic yield gap

Fed holds rates above 4% while ECB cuts toward 2%, widening transatlantic yield gap

The Federal Reserve maintains restrictive policy as the European Central Bank continues easing, creating a 200+ basis point divergence in 2-year yields. Dollar assets draw capital from European markets as US rates hold above 4% while ECB targets 2%. The split reshapes global currency and equity flows.

ViaNews Editorial Team•
Fed Rate Freeze Through Mid-2026 Squeezes Global Credit Markets as $3.2 Trillion Debt Wall Looms

Fed Rate Freeze Through Mid-2026 Squeezes Global Credit Markets as $3.2 Trillion Debt Wall Looms

The Federal Reserve will hold rates steady through June 2026 as U.S. services inflation persists above 3.5%, creating ripple effects across global credit markets. Corporate treasurers worldwide face $3.2 trillion in maturing debt with refinancing costs 150-200 basis points higher than expiring obligations. The prolonged pause mirrors cautious stances from the Bank of Canada and pressures international investors to shift from rate-cut strategies to yield extraction.

ViaNews Editorial Team•
U.S. Fed Independence Under Threat as $1.1 Trillion Medicaid Cuts Risk Contagion to Global Markets

U.S. Fed Independence Under Threat as $1.1 Trillion Medicaid Cuts Risk Contagion to Global Markets

The One Big Beautiful Bill Act cuts $1.1 trillion from U.S. healthcare, leaving 11.8 million uninsured by 2034 as Fed Chair Jerome Powell's May 2026 departure threatens central bank independence. Markets price 40% odds of political interference in monetary policy by 2027, with Treasury term premiums widening 35 basis points—a risk pattern echoing Turkey's 2018 lira crisis when Erdogan pressured rate cuts.

ViaNews Editorial Team•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com